Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1160308 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $5.54Day +4.92%Mkt cap $1.1B1Y +116.4%Off 52W high −20.9%Vol (1Y) 55.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,781 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest16.7% of sh out |
| Days to cover20.8d |
| 13F net flow (QoQ)+3.01% |
| Top-10 13F concentration60.0% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$129.5M |
| ROE−63.5% |
| Debt / equity0.15× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−8.1% |
| 1Y+116.4% |
| 3Y+54.7% |
| 5Y+332.8% |
| 10Y−78.2% |
| Since incept. (ann.)−22.8% |
Total return through 2026-07-30 · series begins 2011-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)55.2% |
| Ann. volatility (3Y)60.7% |
| Sharpe (1Y)1.65 |
| Sharpe (3Y)0.55 |
| Max drawdown (1Y)−32.0% |
| Max drawdown (3Y)−65.3% |
| Beta (3Y vs SPY)−0.32 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| NEA Management Company, LLC | 24.5M | $134M | 11.96% | +0.0% |
| Bain Capital Life Sciences Investors, LLC | 17.6M | $96M | 8.60% | +0.0% |
| Venrock Adviser, LLC | 13.7M | $75M | 6.71% | +0.0% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 13.6M | $74M | 6.63% | +0.0% |
| TCG Crossover Management, LLC | 12.4M | $67M | 6.04% | +0.0% |
| BlackRock, Inc. | 11.3M | $62M | 5.52% | +1.7% |
| Frazier Life Sciences Management, L.P. | 9.7M | $53M | 4.75% | −1.4% |
| Polar Capital Holdings Plc | 9.5M | $52M | 4.66% | +14.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 103.7% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 27,631,844 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.15 | — | — | — |
| 2025-09-30 | 2025-11-12 | −$0.14 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$0.14 | — | — | — |
| 2025-03-31 | 2025-05-13 | −$0.12 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
